Press Release Details

Cerus Corporation to Release Fourth Quarter and Year End 2006 Financial Results on Thursday, February 22, 2007

February, 08 2007

Conference Call and Webcast to Follow

CONCORD, Calif.--(BUSINESS WIRE)--Feb. 8, 2007--Cerus Corporation (NASDAQ:CERS) announced today that its fourth quarter and year end 2006 financial results will be released on Thursday, February 22, 2007, after the close of the market and will host a conference call and live webcast at 4:30 p.m EST that afternoon. Management will discuss the company's fourth quarter and year end 2006 results, provide an overview of the company, and guidance for 2007.

To access the webcast via the internet, log on to www.cerus.com. Please connect to the company's website at least 15 minutes prior to the conference call to ensure adequate time for any software downloads. Alternatively, you may access the live conference call by dialing 866-383-8108 (U.S.) or 617-597-5343 (International) and dial participant passcode 27219354. A telephone replay will be available approximately two hours after the call through 5:00 p.m. EST, February 27, 2007. To access the replay, please call 888-286-8010 (U.S.) or 617-801-6888 and enter passcode 65485120. The webcast will be archived on www.cerus.com through March 22, 2007.

ABOUT CERUS

Cerus Corporation is a biopharmaceutical company that develops and commercializes novel, proprietary products in the fields of blood safety and immunotherapy to provide safer, more effective medical options to patients in areas of substantial unmet medical needs. In the field of blood safety, the company is developing and commercializing the INTERCEPT Blood System, which is based on the company's proprietary Helinx technology and is designed to enhance the safety of donated blood components by inactivating viruses, bacteria, parasites and other pathogens, as well as potentially harmful white blood cells. In the field of immunotherapy, the company is employing its proprietary attenuated Listeria vaccine platform to develop a series of novel therapies to treat cancer, and it is applying its proprietary Killed But Metabolically Active technology platform in research and development of prophylactic and therapeutic vaccines for infectious diseases. INTERCEPT, INTERCEPT Blood System and Helinx are trademarks of Cerus Corporation.

CONTACT: Cerus Corporation
Myesha Edwards, 925-288-6017
Corporate Communications & Investor Relations

SOURCE: Cerus Corporation

    Global Headquarters

  • 1220 Concord Avenue
  • Concord, CA US 94520
  • +1 925.288.6000

    European Headquarters

  • Stationsstraat 79-D
  • 3811 MH Amersfoort, Netherlands
  • +31 (0) 33 49 60 600